POU2F3 and prostate carcinoma: To validate the expression of POU2F3 at the protein level, we performed POU2F3 immunohistochemistry on a tissue microarray (TMA) of prostate cancer cases containing evaluable material for 22 CRPC patients and 8 NEPC patients.